Sinopharm Group Co., Ltd. Class H
Recent
price
P/E
ratio
div
yld
- -
ROIC.AI
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Semi-annual Revenue
•
in mil. unless spec.Semi-annual Earnings Per Share
•
in mil. unless spec.Semi-annual Dividends Per Share
•
in mil. unless spec.- Similar Companies
- Business
- Sinopharm Group Co. Ltd. engages in pharmaceutical supply chain services with primary operations in the People's Republic of China. The company operates through four main segments: Pharmaceutical Distribution; Medical Devices Distribution; Retail Pharmacy; and Other Business. Its Pharmaceutical Distribution segment focuses on the distribution of a wide range of pharmaceutical products to hospitals, distributors, retail pharmacies, and clinics, leveraging an extensive logistics network for warehousing and transportation. The Medical Devices segment distributes diverse medical devices including diagnostic equipment, surgical instruments, and patient monitoring systems, providing installation and maintenance services. The Retail Pharmacy segment manages and franchises a national network of retail drug stores, offering medications and health products directly to consumers. The Other Business segment encompasses pharmaceutical manufacturing, chemical reagents, laboratory supplies, medical instruments, traditional Chinese medicines, IT services, property management, and consulting. Sinopharm operates with a strong focus on therapeutic areas such as oncology, cardiology, infectious diseases, orthopedics, and radiology, impacting patient outcomes through access to essential medicines and advanced medical technologies. The company provides value-added services encompassing supply chain optimization, inventory management, healthcare consultation, and technology integration. Founded in 2003 and headquartered in Shanghai, Sinopharm is a subsidiary of Sinopharm Industrial Investment Co., Ltd. and maintains extensive relationships with domestic and international manufacturers and healthcare providers. In 2024, Sinopharm reinforced its strategic collaborations by signing a strategic cooperation agreement with Fresenius Kabi (China) Co. Ltd., a partnership dating back to 1982. These agreements aim to expand cooperation in pharmaceutical sales, warehousing, distribution, healthcare, medical care, and wellness sectors, enhancing service quality and product availability within China. The alliance is intended to foster innovation, strengthen supply chain capabilities, and support the development of the medical and health industry both domestically and globally. Recent advancements include the commercialization of new drug therapies developed by affiliated entities and approval for clinical trials of innovative vaccines such as the herpes zoster mRNA vaccine. Sinopharm's operations are bolstered by advanced logistics, supply chain management technologies, regulatory compliance, and ongoing expansion of its product portfolio and retail network, positioning it as a leading pharmaceutical distributor and healthcare services provider in China.
Company News
Sinopharm Group (OTCMKTS:SHTDY) and Pediatrix Medical Group (NYSE:MD) Financial Survey
Woori IO, an OSR Company, Signs NDA with Sinopharm to Explore China Commercial Opportunities
Sinopharm Group (OTCMKTS:SHTDF) Stock Price Crosses Below Two Hundred Day Moving Average – Time to Sell?
Sinopharm Group (OTCMKTS:SHTDF) Stock Price Passes Above 50 Day Moving Average – Time to Sell?
Lakeside Signs $1.5 Million Sales Agreement with Sinopharm Group Subsidiary
Lakeside Strengthens Market Position in China's Pharmaceutical Logistics with Key Sinopharm(Hubei) Contracts
Pandemic Accelerates China's Drive Into mRNA Treatments
Week In Review: WHO Close To Approving Global Use For 2 China COVID-19 Vaccines
Diversifying Into Top-Ranked Sinopharm
Week In Review: Sinopharm Transfers $4.6 Billion In Assets Including Two COVID-19 Vaccines
Week In Review: Eluminex Raises $50 Million For Ophthalmology Drugs